Although yesterday’s news in relation to VR315 (generic Advair®) was disappointing, our estimates for the product were already conservative (hence our downgrade to Sell ahead of the original GDUFA date in May 2017, following which we moved to Hold). VR315 currently represents 19.5p of our 113p target price (25% upside from the current level). We upgrade to Buy.
10 Nov 2017
N+1 Singer - Vectura Group - Undervalued after share price fall: upgrading to Buy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vectura Group - Undervalued after share price fall: upgrading to Buy
- Published:
10 Nov 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
Although yesterday’s news in relation to VR315 (generic Advair®) was disappointing, our estimates for the product were already conservative (hence our downgrade to Sell ahead of the original GDUFA date in May 2017, following which we moved to Hold). VR315 currently represents 19.5p of our 113p target price (25% upside from the current level). We upgrade to Buy.